Many vaccine proteins are extensively modified with sugars (glycans), but it has been difficult until recently to produce pure glycoforms of such vaccine proteins. This has obstructed the targeted engineering of the sugar structures for studying and improving vaccine efficacy. New biotechnology being developed at Ghent University overcomes this research bottleneck, which may lead to new vaccines for allergy, flu and worm infections.